519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs

BACKGROUND: Remdesivir is FDA-approved for the treatment of hospitalized patients with severe COVID-19. Many patients improve clinically to allow for hospital dismissal before completing the 5-day course. In prior work, those who continued remdesivir in an outpatient setting had better outcomes. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesdachai, Supavit, Rivera (O'Connor), Christina G, Rosedahl, Jordan K, Philpot, Lindsey, Dholakia, Ruchita, Borah, Bijan J, Draper, Evan, Arndt, Richard, Ganesh, Ravindra, Larsen, Jennifer J, Destro Borgen, Molly J, Razonable, Raymund R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678783/
http://dx.doi.org/10.1093/ofid/ofad500.588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678783/
http://dx.doi.org/10.1093/ofid/ofad500.588

Ejemplares similares